The aim of this study was to evaluate the effect of arsenic trioxide as a single agent in acute promyelocytic leukaemia cases for induction, consolidation, and maintenance therapy in a long-term, 11-year follow-up. We studied 60 patients with acute promyelocytic leukaemia. Sixty percent of the patients were aged between 12 and 24 years. Arsenic trioxide was infused at a 0.15 mg/kg daily dose until complete remission was achieved. After 2 weeks of rest, arsenic trioxide was infused daily for 28 days as a consolidation therapy. Then, arsenic infusions were given every 3-4 months for 14 days for 2 years, and the patients were followed until relapse or death. The rates of complete remission, disease-free survival, overall survival, and drug toxicity were evaluated. The morphologic complete remission was observed in 55 out of the 60 patients. The most common causes of a remission failure were early mortality because of the APL differentiation syndrome and the lack of response to arsenic treatment. The mean follow-up was 90 months. The primary outcomes for males and females were a mean disease-free survival of 101 and 97 months, respectively, and a mean overall survival of 103 and 101 months, respectively. From the 55 cases with remission, three patients died (late mortality). Of the 60 patients, 85% are still alive. Arsenic trioxide was generally well tolerated. The long-term follow-up of patients with APL, treated with arsenic alone as induction, consolidation, and maintenance therapy, shows high cure rates and excellent outcomes.
Introduction
Acute promyelocytic leukaemia (APL) is subtype M3 according to the French-American-British (FAB) classification [1] of acute myeloid leukaemia (AML) and represents approximately 10%-15% of AML [1] with a different biological and clinical behaviour, a chromosomal translocation (15; 17) [2] that causes the accumulation of abnormal promyelocytes in the bone marrow and peripheral blood [3, 4] . Promyelocytes contain tissue factor and procoagulants that can be released into the plasma because of promyelocyte damage either spontaneously or induced by chemotherapy, and predispose patients to severe bleeding [5] [6] [7] or exacerbate the coagulopathy. Such a presentation is life-threatening and the worst complication of acute promyelocytic leukaemia, which occurs predominantly at early ages. The bleeding diathesis is caused by disseminated intravascular coagulation and also by primary fibrinolysis [8] . Fibrinolysis may be caused by expression of annexin II, a cell surface receptor for plasminogen and tissue plasminogen activator, at abnormally high levels on APL cells [8, 9] . Chemotherapy exacerbates bleeding disorder. Leukopenia is the most presentation in PBS patients with APL. Interestingly, two other translocations exist in this leukaemia. The microscopic morphology in these three translocations is different in the peripheral blood and bone marrow. Currently, remission induction therapy with all-trans-retinoic acid (ATRA) in combination with chemotherapy is an accepted treatment for acute promyelocytic leukaemia [5, 10] , resulting in cure rates of 80% during the induction phase to control hyperleukocytosis and the subsequent outcome, i.e. the retinoid syndrome; it is necessary to combine chemotherapy with ATRA. The prevalence of retinoic syndrome while using ATRA has been reported 6% to 31%, and there are also some long-term complications. These include myeloid sarcoma at the time of relapse [11] , cardiac dysfunction [12, 13] , myelodysplastic syndromes [14] , and secondary malignancies. New strategies using arsenic trioxide (ATO) in the treatment of new patients with APL may possibly eliminate early and late complications. This drug was proposed as a new medicine by Chinese studies on APL treatment. Using arsenic in acute promyelocytic leukaemia is approved by the FDA and the benefit of ATO in a primary setting for the treatment of APL has been reported and complete remission (CR) has been induced in approximately 80% of patients [15, 16] . ATO targets PML/RARA and exerts dose-dependent dual effects on APL cells [2, 7, [15] [16] [17] [18] [19] and induces maturation and apoptosis and finally complete remission [20] . Molecular remission is obtainable in 72 to 91% of patients after CR induced by ATO as a single agent [21, 22] .Consolidation therapy is started for these patients after entering remission [10] . Despite the potential for cure with ATO, approximately 20-30% of patients relapse without long-term maintenance therapy and require salvage therapy [23] . The importance of maintenance therapy has been demonstrated in recent reports. Intergroup Study I0129 [21] and the European APL Group APL 93 [24] confirmed the benefit of maintenance therapy. The most important factors used in the maintenance therapy are methotrexate and ATRA which reduce relapse [25, 26] . The efforts have been focused on interventions that can extend disease-free survival and reduce the relapse rate. Using arsenic was our strategy for treatment in induction, consolidation [3, 27] , and maintenance [18] phases in patients with acute promyelocytic leukaemia to extend disease-free survival [28] and reduce the relapse rate. The use of ATO as consolidation and maintenance therapy eliminated the need for chemotherapy and improved both disease-free survival (DFS) and overall survival (OS) rates. Thus, this agent was reasonably effective and produced a good survival rate [15, 21, 22, 27] . The major toxicity of ATO treatment during remission induction is APL differentiation syndrome or retinoic acid syndrome. This complication is reported in about a third of patients. The syndrome is treated with dexamethasone at a dose of 8 mg TDS. If necessary, assisted ventilation is used for patients whose APL differentiation syndrome progressed to the adult respiratory distress syndrome, and activated factor VII (NovoSeven) is used for patients with bleeding [29] . A non-randomized study has suggested some benefits of prophylactic corticosteroids to prevent the syndrome in APL cases treated by alltrans retinoic acid [30] . QT prolongation on electrocardiogram and sometimes torsades de point arrhythmia were seen in APL cases treated with arsenic trioxide, which can cause sudden cardiac-related death. Other toxicities include leukocytosis, peripheral neuropathy, lightheadedness, musculoskeletal pain, hyperglycemia, fluid retention, and skin discoloration. During the consolidation phase, occurrence of these complications is very rare, so it is possible that complications are because of toxic effects of the drug and toxic products of leukemic cells. Considering our experience in this field and to update our previous study, we followed up 60 patients with APL for 12 years using arsenic for induction, consolidation, and maintenance therapy as 14-day periods every 3 to 4 months for 2 years. In this retrospective study, we examined overall response rate, relapse-free survival, overall survival, and short-and long-term complications in patients treated with arsenic.
Materials and methods
From October 2005 to February 2015, 60 patients with acute promyelocytic leukaemia attending Taleghani and Imam Reza hospitals in Kermanshah were entered into this study. APL was diagnosed based on French-AmericanBritish (FAB) morphological classification criteria and clinical symptoms and cytogenetic testing or FISH testing for T (15; 17) . These centres are referral centres for patients from Kurdistan, Hamedan, Ilam, and Lorestan provinces. Exclusion criteria included pregnancy and hepatic dysfunction.
Remission induction
After diagnosis of APL according to the above criteria, the initial dose of 0.15 mg per kilogramme of body weight per day of arsenic in 500 mL of dextrose water as a 2-h intravenous infusion was started for the patients, and continued until complete remission was achieved based on the morphologic complete remission criteria or to a maximum of 45 days. No chemotherapeutic agents were used during the treatment.
Protective measures during treatment
During treatment, CBC differentiation, platelets, the prothrombine time, the activated partial thromboplastin time, and fibrinogen were measured at the time of diagnosis and regularly during the treatment and electrocardiogram were requested and QTc intervals measured for the patients every day. Potassium, calcium, magnesium, kidney and liver function tests, and blood glucose were checked twice a week. Patients were weighed daily, so they could be monitored more closely if they gained weight and there was a possibility of APL differentiation syndrome. To reduce the incidence of this complication and increase the effect of arsenic in patients, the (in order of entering the study) the second 30 patients received dexamethasone in the first week after the diagnosis along with arsenic. Administration of platelets was requested for patients with platelets less than 50 000/μL. Arsenic was discontinued if bilirubin increased above 5 mg per/dL and liver enzymes were three times the normal value, and resumed when they were normal again. Patients were observed during treatment in terms of arsenic complications. Criteria for administration of plasma and cryoprecipitate were not impaired PTT and PT and decreased fibrinogen, but they were administrated for patients only if they were on the verge of bleeding or if they bled.
Consolidation therapy
After 14 days of rest, consolidation therapy was started. Arsenic was started during the 28 day for surviving patients as outpatient. During consolidation therapy, patients visited every week and a complete blood count, a liver function test, and an electrocardiogram were evaluated, and then all patients received maintenance therapy
Maintenance therapy
Arsenic was administered for 14 days for patients every 3 to 4 months for two years and patients were also examined for signs of relapse; only two patients refused the treatment and were not entered into the study.
Response definition
Complete remission is defined as blast criteria less than 5%, abnormal promyelocytes less than 5%, platelets over 100 000 and clinical and laboratory DIC remission.
Statistical analysis
Overall survival (from the start of treatment to death or statistical record time) and disease-free survival (from the start of treatment to relapse time) is calculated according to the Kaplan-Meier curve. Early and late mortality rate is calculated.
Results
Mean follow-up was 90 months. Sixty percent of patients were between 12 and 24 years old, 24 were female and the 36 were male. From a total of 60 cases, 55 patients went into remission and the total response rate 92%. Fifty-three percent of the patients had at least one complication from the disease and treatment. The most common clinical symptoms were DIC clinical (55%), hyperleukocytosis (13.3%), and febrile neutropenia (43.3%). One patient had myeloid sarcoma (MS), and another had vein thrombosis in central nervous system (CNS). Two patients exclude maintenance. We had five early mortalities; two cases were because of APL differentiation and the rest were because of lack of response to arsenic treatment and died. Patients' death was caused by pulmonary and cerebral haemorrhage. Three patients died during the follow-up period (late mortality). No significant complication of long QT syndrome occurred during induction, consolidation, and maintenance therapy with arsenic. With the increase in white cell count above 60 000, arsenic dose was reduced 50%. In the case of increase in cell count above 100 000 for patient, anthracyclines (daunorubicin) (13.3%) was administered at a dose of 30 mg per square metre for 1 to 2 days. In this study, we had to administer low dose daunorubicin for eight patients; seven cases were attributed to an increase in cell count and one case to lack of response to arsenic treatment. In seven patients, white blood cell counts were >100 000/mm 3 . There was a case of spinal myeloid sarcoma that received systemic radiation therapy to the lumbar spine. From a total of 55 patients, six had relapse, and three of them died (late mortality). The primary outcomes for males and females were a mean disease-free survival of 101 and 97 months, respectively (overall 99 months; Figure 1) , and a mean overall survival of 103 and 108 months, respectively (overall 102 months; Figure 2 ). Confidence intervals for the mean disease-free survival and mean overall survival in terms of recurrence and death are shown in Figures 3 and 4 . Of the 60 patients, 85% are still alive.
Patients who had relapse were treated with ATRA and arsenic with the exception of one patient who had four re- lapses, who was given only arsenic because they could not purchase ATRA. This was our oldest patient and is still alive and in remission. Although he is a candidate for stem cell transplantation, it is not possible because of his poor financial status. Finally, eight patients died. No specific side effects occurred that can be specifically attributed only to arsenic including skin lesions, gastrointestinal disturbances and headache, and arsenic was tolerated very well. Twelve patients redeveloped leukopenia (less than 3000) when the cell count was normal (treatment-related neutropenia), but it stopped after administering neupogen for 2 days and began to rise to normal levels. No electrolyte imbalance and hypoglycemia were observed in patients. Renal and hepatic and neurological toxicity was not observed. Asymptomatic long QT was observed in 20% of patients. No significant symptomatic electrocardiogram abnormalities occurred.
No malignancies, MDS, and cardiac dysfunction were observed during a 12-year follow-up, and arsenic was completely safe.
Discussion
Arsenic is a potential agent for the treatment of acute promyelocytic leukaemia. The only significant toxicity that occurred for our patients was hyperleukocytosis which occurred in seven patients in total; five cases in the first 30 patients and two cases in the next 30 patients. It may be attributed to dexamethasone which makes arsenic effect faster. We started dexamethasone for the second 30 patients (in order of entering the study) if they were not at the risk of infection. Dexamethasone was discontinued before completion of the course and with the onset of infection or fever. APL differentiation was only observed in five patients, of whom four were in the first 30 patients and only one in the second 30 patients. During the treatment with ATO, there was no bone marrow suppression, and only limited leucopenia side effect was encountered. This may also be attributed to dexamethasone. During the consolidation and maintenance therapy, no toxicity was documented for our patients. The major concern associated with a long-term exposure to ATO is a late complication. In the 12-year follow-up, complications such as MDS, delayed cardiomyopathy and secondary malignancies were not observed in patients who used arsenic. This study also showed reduced haematological toxicity compared with ATRA and chemotherapy. Medical complications were observed during induction period and no complication was seen during consolidation and maintenance therapies. Two strategies were in uses Arsenic in our study. The first strategy in acute promyelocytic leukaemia is timely diagnosis and Start treatment immediately, which reduces mortality. The second strategy for reducing relapse is using arsenic as consolidation and maintenance therapy, which begins after induction in patients with remission. This study shows that the use of ATO as induction, consolidation, and maintenance therapy for adult patients with newly diagnosed APL significantly improves complete remission, DFS, and OS.
Conclusion
Arsenic is a potential agent for the treatment of acute promyelocytic leukaemia. In addition to complete remission, we had a significant survival rate through consolidation and maintenance therapy. The safety profile of the drug is favourable. Arsenic is a safe medicine with no chronic and important complications, and it is time to consider it as a first-line treatment.
